Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Arm or belly? study seeks best spot for blood clot shot in severe obesity

NCT ID NCT07213713

Knowledge-focused Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether injecting the blood thinner enoxaparin into the arm or the abdomen works better for preventing blood clots in people with severe obesity (BMI over 40). Researchers will measure drug levels in the blood to see which injection site gives the right amount. The study plans to enroll 80 adults who need clot prevention.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
enoxaparin
What this could lead to
If successful, this could show the best injection site for enoxaparin in people with severe obesity, improving clot prevention.
What could go wrong
This is a small, early-stage study (80 people) that only measures drug levels, not actual clot prevention. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Prospective observational study, multicentric. Target population: Patients with BMI 40 kg/m2 hospitalized, candidates for anticoagulation therapy in prophylaxis (PADUA score 4).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria:• age \>18 years, * BMI \>40 kg/m2 * indication to primary or secondary thromboprophylaxis (Padua Score \> 4), as clinical practice Exclusion Criteria:• indication to full dose anticoagulant, * creatinine clearance \<30 mL/min (based on Cockcroft-Gault equation using adjusted body weight), * pregnant women, * low platelet count (\<50.000/microL or \<100.000/microL plus additional risk factors for bleeding), * active bleeding, * active gastroduodenal ulcer, * severe bleeding diathesis, * recent/planned/emergency high bleeding-risk surgery/procedure, * major trauma, * acute intracranial hemorrhage, * bleeding within the three months prior to admission, * known hypersensitivity to enoxaparin (e.g. pruritus, urticaria, anaphylactic/anaphylactoid reactions), * history of immune mediated heparin-induced thrombocytopenia (HIT), * severe uncontrolled hypertension, * diabetic or hemorrhagic retinopathy, * concurrent administration of subcutaneous drugs (i.e. insulin, GLP-1 receptor agonists, etc.).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obese patients are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

morbid obesity obesity disorder venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obese patients Venous thromboembolism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.